Sales of the company’s spinal implants and heart defibrillators, which account for about 40 percent of total sales, had been weak for more than a year and were down 5 percent this quarter as well. Overall revenue reached $4.13 billion and was boosted by sales of heart valves, stents and other upgraded products.
Related Articles on Medical Devices:
FDA Clears Aptus Endosystems EndoStapling System
Doctors Question the Value of Robot-Assisted Surgery
FDA Studying New Heart Stents that Stretch After Implantation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.